Scotiabank Initiates Coverage on Gossamer Bio with Positive Outlook and $11 Price Target

Scotiabank initiates coverage of Gossamer Bio (GOSS) with an Outperform rating and a $11 price target, citing the company's innovative strategies in addressing pulmonary arterial hypertension and pulmonary hypertension linked with interstitial lung diseases. The firm believes Gossamer Bio's primary drug candidate, seralutinib, has the potential to gain traction due to its unique action as an inhaled tyrosine kinase inhibitor. The average target price for Gossamer Bio is $8.60, with a high estimate of $15.00 and a low estimate of $4.00, implying an upside of 532.35% from the current price.

Scotiabank has initiated coverage of Gossamer Bio (GOSS) with an Outperform rating and a $11 price target, citing the company's innovative strategies in addressing pulmonary arterial hypertension (PAH) and pulmonary hypertension linked with interstitial lung diseases. The firm believes Gossamer Bio's primary drug candidate, seralutinib, has the potential to gain traction due to its unique action as an inhaled tyrosine kinase inhibitor.

The average target price for Gossamer Bio is $8.60, with a high estimate of $15.00 and a low estimate of $4.00, implying an upside of 532.35% from the current price. Scotiabank's analysis highlights the company's strong pipeline and the potential for seralutinib to become a first-in-class treatment for PAH.

Gossamer Bio's recent clinical trial outcomes and regulatory submissions have demonstrated the drug's promising efficacy. The company's Phase 3 PROSERA Study, evaluating seralutinib in Functional Class II and III PAH patients, successfully completed enrollment in June 2025. Topline results from this study are anticipated in February 2026.

The firm also noted that Gossamer Bio's collaboration with the Chiesi Group under a global agreement further strengthens the company's position in the PAH market. Scotiabank's report underscores the potential for seralutinib to address an unmet medical need, with the drug under review by the U.S. Food and Drug Administration (FDA).

Gossamer Bio has also presented its work on seralutinib at the Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress, showcasing the drug's preclinical evidence and clinical progress. These presentations highlight the ongoing research and development efforts aimed at improving the lives of patients facing serious pulmonary conditions.

Scotiabank's Outperform rating reflects the firm's confidence in Gossamer Bio's ability to deliver on its promises and capitalize on the growing demand for innovative PAH treatments. The $11 price target suggests that the market may underestimate the drug's potential, offering a significant upside for investors.

References:
[1] https://www.marketbeat.com/stocks/NASDAQ/GOSS/fda-events/